Supply Chain

Agreement is centered around expanding medication access to patients

In deal to be finalized by October, purchases B Medical Systems for $423 million

Growth of CDMO's Pennsylvania facility will feature increase in cold chain storage capacity

Pharmaceutical distribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own

Six steps pharma organizations can follow to help achieve sustainability in their product supply chains

Acquisition of healthcare logistics company to play a role in delivery of pharma and biologic treatments

Association’s director general recommends air cargo developments be closely monitored in second half of year

Cold chain logistics deal expands business’ international reach

Center will feature a $1.4 billion investment plan

Partnership allows for distribution of packager’s temperature-controlled container

Production capacity for the contract manufacturer is expected to more than triple

Partnership with Thoughtworks expected to increase transparency, streamline processes

Easing of Omicron restrictions in China played a role, association notes

The EPCIS communications standard is “recommended,” and trading partners are identified

With a cost of approximately $514 million, expected completion is 2026

Logistics experts provide an outlook on what the industry must do to overcome potential bottlenecks

A conversation with ZS’s Maria Whitman and Anshul Agarwal

Marks the CDMO’s second plant in the country

Outlining ways visibility technology is solving pharma supply chain problems at a crucial time—and how digitization is the key

Containers to potentially be operational by next year, 2024 at the latest

Features an ATP solution to allow for efficiency

New Garner, NC location will be its first outside the Midwest

Will serve as a hub, as company aims for growth in the European region

A conversation with EY life sciences leaders Jim Welch and Jay Welsh

Proper control of type 1 and 2 diabetes can greatly reduce the personal impact and economic burden of this pervasive public health condition. To that end, stakeholders are exploring many parallel routes to help individuals and society maintain the upper hand, as the toll of diabetes continues to skyrocket